Grifols' Plasma Pioneers: Meet The Scientists Leading The Charge Against Rare Diseases

Our history includes breakthroughs such as the development of the plasmapheresis.

Verkkosince our founding in 1909, we have worked to advance plasma science.

Verkkoa pioneer in the plasma industry, grifols continues to grow its network of donation centers, the world’s largest with over 390 across north america,.

Verkkogrifols created the grifols chair for the study of cirrhosis in 2015 to promote research and awareness of liver disease, with an emphasis on cirrhosis.

Verkkothe transaction bolsters grifols’ standing as a global leader in fractionation capacity (20 million liters plasma/year) and operator of europe’s.

Verkkoproteins are used to treat rare diseases such as haemophilia, primary immunodeficiencies and α1 antitrypsin deficiency, but they have even greater.